Denison, Hayley JWorswick, JuliaBond, Christine M.Grimshaw, Jeremy MMayhew, AlainRamadoss, Shakila GnaniRobertson, ClareSchaafsma, Mary EllenWatson, Margaret C.2021-08-232021-08-232020-08-24Denison, H J, Worswick, J, Bond, C M, Grimshaw, J M, Mayhew, A, Ramadoss, S G, Robertson, C, Schaafsma, M E & Watson, M C 2020, 'Oral versus intra‐vaginal imidazole and triazole anti‐fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)', Cochrane Database of Systematic Reviews, no. 8, CD002845. https://doi.org/10.1002/14651858.CD002845.pub3.1469-493Xhttps://hdl.handle.net/2164/16979Internal sources: • Health Services Research Unit, University of Aberdeen, UK • Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Canada (Salary support for Julia Worswick) • Centre of Academic Primary Care, University of Aberdeen, UK External sources: • JMG holds a Tier 1 Canadian Research Chair in Knowledge Transfer and Uptake, Canada • MCW was funded by a Health Foundation Improvement Science Fellowship and the University of Strathclyde, UK • The Health Services Research Unit is funded by the Chief Scientist ODice, Scottish Executive Health Department, UK • The Health Economic Research Unit is funded by the Chief Scientist ODice, Scottish Executive Health Department, UK113943845engSDG 3 - Good Health and Well-beingAcute diseaseAdministrationIntravaginaladministrationoralantifungal agentscandidiasisvulvovaginalcost-benefit analysisimidazolesRandomized Controlled Trial as topicTriazolesfemalehumansR MedicinePharmacology (medical)RJournal article10.1002/14651858.CD002845.pub3.http://www.scopus.com/inward/record.url?scp=85089921167&partnerID=8YFLogxK8